Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Vivian Ruvolo"'
Autor:
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B. Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E. Hughes, Phuong K. Morrow, Torsten Haferlach, Steven Kornblau, Muharrem Muftuoglu, Michael Andreeff
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available treatments, including venetoclax-based drug combinations and pose a major therapeutic challenge. Analyses of RNA sequencing and reverse phase protein array datase
Externí odkaz:
https://doaj.org/article/ed4c5f0838c540e4bdf8c2b8285492df
Autor:
Natalia Baran, Alessia Lodi, Yogesh Dhungana, Shelley Herbrich, Meghan Collins, Shannon Sweeney, Renu Pandey, Anna Skwarska, Shraddha Patel, Mathieu Tremblay, Vinitha Mary Kuruvilla, Antonio Cavazos, Mecit Kaplan, Marc O. Warmoes, Diogo Troggian Veiga, Ken Furudate, Shanti Rojas-Sutterin, Andre Haman, Yves Gareau, Anne Marinier, Helen Ma, Karine Harutyunyan, May Daher, Luciana Melo Garcia, Gheath Al-Atrash, Sujan Piya, Vivian Ruvolo, Wentao Yang, Sriram Saravanan Shanmugavelandy, Ningping Feng, Jason Gay, Di Du, Jun J. Yang, Fieke W. Hoff, Marcin Kaminski, Katarzyna Tomczak, R. Eric Davis, Daniel Herranz, Adolfo Ferrando, Elias J. Jabbour, M. Emilia Di Francesco, David T. Teachey, Terzah M. Horton, Steven Kornblau, Katayoun Rezvani, Guy Sauvageau, Mihai Gagea, Michael Andreeff, Koichi Takahashi, Joseph R. Marszalek, Philip L. Lorenzi, Jiyang Yu, Stefano Tiziani, Trang Hoang, Marina Konopleva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
Notch1 is frequently activated promoting T-cell acute lymphoblastic leukaemia (T-ALL). Here, the authors show that Notch1 induces oxidative phosphorylation dependency in T-ALL and synergism when inhibiting both mitochondrial complex I and glutaminoly
Externí odkaz:
https://doaj.org/article/3982d909df0b4071b01a6f0797433bde
Autor:
Weiguo Zhang, Guopan Yu, Hongying Zhang, Mahesh Basyal, Charlie Ly, Bin Yuan, Vivian Ruvolo, Sujan Piya, Seemana Bhattacharya, Qi Zhang, Gautam Borthakur, Venkata Battula, Marina Konopleva, William G. Rice, Michael Andreeff
Publikováno v:
Haematologica, Vol 108, Iss 6 (2022)
Strategies to overcome resistance to FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed. We identified autophagy as one of the resistance mechanisms, induced by hypoxia and the bone marrow microenvi
Externí odkaz:
https://doaj.org/article/fc214a4663764cf4a1afa569299e8742
Autor:
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B. Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E. Hughes, Phuong K. Morrow, Torsten Haferlach, Steven Kornblau, Muharrem Muftuoglu, Michael Andreeff
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/3a3640a997424898be13fe344335ea7a
Autor:
Kotoko Yamatani, Tomohiko Ai, Kaori Saito, Koya Suzuki, Atsushi Hori, Sonoko Kinjo, Kazuho Ikeo, Vivian Ruvolo, Weiguo Zhang, Po Yee Mak, Bogumil Kaczkowski, Hironori Harada, Kazuhiro Katayama, Yoshikazu Sugimoto, Jered Myslinski, Takashi Hato, Takashi Miida, Marina Konopleva, Yoshihide Hayashizaki, Bing Z. Carter, Yoko Tabe, Michael Andreeff
Publikováno v:
Translational Oncology, Vol 18, Iss , Pp 101354- (2022)
Tyrosine kinase inhibitors (TKIs) are established drugs in the therapy of FLT3-ITD mutated acute myeloid leukemia (AML). However, acquired mutations, such as D835 in the tyrosine kinase domain (FLT3-ITD/D835), can induce resistance to TKIs. A cap ana
Externí odkaz:
https://doaj.org/article/5f829a8f3d514045bac9ac8ddf376118
Autor:
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Marc Warmoes, Philip L. Lorenzi, Duncan Mak, Vivian Ruvolo, Lin Tan, Justin Cidado, Lisa Drew, Michael Andreeff
Publikováno v:
Haematologica, Vol 107, Iss 1 (2020)
MCL-1 and BCL-2 are both frequently overexpressed in acute myeloid leukemia (AML) and critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in venetoclax resistance. Using genetic and pharmacological approaches, we discover
Externí odkaz:
https://doaj.org/article/fffc4ffdded640ba994ff0a9a7c7bbd8
Autor:
Bin Yuan, Fouad El Dana, Stanley Ly, Yuanqing Yan, Vivian Ruvolo, Elizabeth J Shpall, Marina Konopleva, Michael Andreeff, Venkata Lokesh Battula
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242809 (2020)
The bone marrow microenvironment (BME) in acute myeloid leukemia (AML) consists of various cell types that support the growth of AML cells and protect them from chemotherapy. Mesenchymal stromal cells (MSCs) in the BME have been shown to contribute i
Externí odkaz:
https://doaj.org/article/0adf49e4d52e49deb990f77bac8077f9
Autor:
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI
Externí odkaz:
https://doaj.org/article/0bd8e62d967643b3a9da152f3ac965a1
Autor:
Jo Ishizawa, Kensuke Kojima, Teresa McQueen, Vivian Ruvolo, Dhruv Chachad, Graciela M Nogueras-Gonzalez, Xuelin Huang, William E Pierceall, E J Dettman, Michael H Cardone, Sharon Shacham, Marina Konopleva, Michael Andreeff
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138377 (2015)
BH3 profiling measures the propensity of transformed cells to undergo intrinsic apoptosis and is determined by exposing cells to BH3-mimicking peptides. We hypothesized that basal levels of prosurvival BCL-2 family proteins may modulate the predictiv
Externí odkaz:
https://doaj.org/article/ead11efec0f743f38ce7ba3468175453
Autor:
Gautam Borthakur, Seshagiri Duvvuri, Vivian Ruvolo, Durga Nand Tripathi, Sujan Piya, Jared Burks, Rodrigo Jacamo, Kensuke Kojima, Peter Ruvolo, Juan Fueyo-Margareto, Marina Konopleva, Michael Andreeff
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139254 (2015)
MDM2 (mouse double minute 2) inhibitors that activate p53 and induce apoptosis in a non-genotoxic manner are in clinical development for treatment of leukemias. P53 can modulate other programmed cell death pathways including autophagy both transcript
Externí odkaz:
https://doaj.org/article/1e29b2e8f776433bb52a37ec5080a36e